BEIJING, Nov. 28 (Xinhua) -- A total of 70 new drugs will be included in China's national medical insurance catalog with their prices slashed by 60.7 percent on average, said the National Healthcare Security Administration (NHSA) Thursday.

Eight domestically-produced drugs that are seen as "major innovations" and have just hit the market in recent years are among the new additions, said the NHSA at a press conference.

Some 22 anti-cancer drugs, seven drugs for rare diseases, 14 for chronic diseases and four for children will be included in the catalog, and the prices of three new drugs for hepatitis C will be reduced by an average of 85 percent, according to the NHSA.